Imaging company Exact Imaging revealed on Wednesday the receipt of Health Canada's approval for its FusionVu application for micro-ultrasound/MRI fusion using the ExactVu high resolution micro-ultrasound system for the highest real-time resolution for targeted prostate imaging and biopsy.
This approval allows the company's Canadian customers to use the FusionVu application.
In addition, the company's ExactVu micro-ultrasound system and FusionVu have received regulatory approval in the EU (CE Mark), the US(FDA 510(k)) and Canada (Health Canada medical device license).
The company said the ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. The urologists are able to visualise areas of interest in the prostate and specifically target biopsies at those areas using the Exact Imaging platform.
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission
Tempus secures FDA clearance for RNA-based xR IVD diagnostic device
Shoulder Innovations expands I-Series portfolio with launch of InSet 70 Humeral Stem
GSK commits USD30bn to US R&D and manufacturing expansion
ArtPlayer Promotes Elderly Wellbeing with Digital Signage and Streaming Art in Finnish Care Homes
Implantica produces 10,000 RefluxStop units ahead of planned US launch